The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
ELARA: 4-year follow-up of tisagenlecleucel in patients with R/R FL
|
The phase II ELARA trial (NCT02500407) assessed the safety and efficacy of tisagenlecleucel, a CAR T-cell therapy, in patients with R/R FL after ≥2 prior lines of therapy.1 Based on results from this trial, tisagenlecleucel was approved for treatment of these patients by the EC and received priority review by the FDA. The Lymphoma Hub reported previously on outcomes from the ELARA trial (N = 97 infused). The 4-year follow-up results were presented at the 66th ASH Annual Meeting and Exposition by Thieblemont.1 The data cut-off was March 27, 2024, and study endpoints were CRR, PFS, OS, ORR, and safety.1 |
| Key learnings |
| At a median follow-up of 53 months, the CRR was 69.1%. Subgroup analysis suggests that most baseline high-risk disease characteristics (double-refractory disease, bulky disease, POD24, and high FLIPI) were not associated with inferior outcomes. |
| Median PFS was 53.3 months and 48-month PFS was 50.2%; median OS was not reached; 48-month OS was 79.3%; ORR was 66.1%. |
| No new safety signals have been reported since the last data cut-off. Grade ≥3 TEAEs occurred in 28.6% of patients. |
| Long-term follow-up data from the ELARA trial demonstrate robust, durable responses with a tolerable safety profile of tisagenlecleucel >4 years post infusion regardless of high-risk disease characteristics, supporting its use in patients with R/R FL. |
Abbreviations: CRR, complete response rate; EC, European Commission; FDA, U.S. Food and Drug Administration; FL, follicular lymphoma; FLIPI, Follicular Lymphoma International Prognostic Index; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; POD24, progression of disease within 24 months from the start of first-line therapy; TEAE, treatment-emergent adverse event; R/R, relapsed/refractory.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
